A strategy for advance care planning (ACP) that included automated outreach from staff who contacted patients to offer assistance significantly boosted the number of patients who completed documentation outlining their wishes in…
Author: admin
-

X-Ray Mystery: Magnetized Neutron Star NGC 7793 P13
When gas falls onto a compact object, such as a neutron star or black hole, due to its strong gravity (a process called accretion), it emits electromagnetic waves. High-sensitivity observations have discovered objects with extremely…
Continue Reading
-

Tomb Raider: Legacy Of Atlantis Is A Remake Of The First Game In The Series
Crystal Dynamics and developer Flying Wild Hog have revealed Tomb Raider: Legacy of Atlantis, a remake of the very first Tomb Raider game, which originally launched in 1996. The reveal trailer shows a Lara Croft reminiscent of her 1996 design…
Continue Reading
-

Lara Croft returning in new games coming in 2026 and 2027
The ambitious next chapter of Lara Croft’s story, Tomb Raider: Catalyst, which has been in development by Crystal Dynamics since 2022, marks a bold new direction for the series as Lara embarks on an all-new adventure across Northern India….
Continue Reading
-

Watch Taylor Swift ‘The End of an Era’ Docuseries, Concert Online Free
If you purchase an independently reviewed product or service through a link on our website, The Hollywood Reporter may receive an affiliate commission.
One year after Taylor Swift‘s record-breaking Eras Tour came to a close, the 14-time…
Continue Reading
-

How a Single Gene Shapes Leaf Lobes in Brassica Rapa
Brassica crops, such as B. rapa, often display variations in leaf shape, including entire or lobed leaves, which significantly impact their adaptability and agricultural utility. Lobed leaves offer benefits such as…
Continue Reading
-

CM surprises students with unannounced visit
Afridi urges actionable steps for UoP financial self-sufficiency, enhanced student facilities
Khyber-Pakhtunkhwa Chief Minister Muhammad Sohail Afridi. Photo: File
…Continue Reading
-

Pakistan’s health minister launches last nationwide polio campaign of 2025, notes decline in cases
December 12, 2025
ISLAMABAD – Pakistan is one of the last two countries in the world, alongside Afghanistan, where polio remains endemic. So far, the country has recorded 30 polio cases, with the highest number of cases in Khyber Pakhtunkhwa…
Continue Reading
-

Asian Stocks Jump After Global Gauge Hits New Peak: Markets Wrap
(Bloomberg) — Asian stocks rallied after gauges of US and global equities hit fresh records, with sentiment boosted by this week’s Federal Reserve’s rate cut and its upbeat assessment of the US economy.
MSCI Inc.’s index of Asian shares was up 0.9% on Friday, poised for its highest close in about a month. Japan’s Topix led regional gains, with financials favored on bets that a Bank of Japan interest-rate hike next week is all but certain. Chinese equities underperformed after the nation’s leadership signaled it will maintain economic support but refrain from ramping up stimulus next year.
While the S&P 500 climbed 0.2% to an all-time high on Thursday, some caution for tech names persisted. Shares of Broadcom Inc., a chip company vying with Nvidia Corp. for AI computing revenue, slid in late trading after its sales outlook for red-hot market failed to meet investors’ lofty expectations. S&P 500 futures were steady on Friday though contracts on the tech-heavy Nasdaq 100 fell 0.1%.
Thursday’s price action lifted the MSCI All Country World Index — one of the broadest measures of the stock market — to a new closing high. Up nearly 21% in 2025, it is on track for its best year since 2019.
“The momentum should continue into year-end. With rate cuts underway, a new Fed chair on deck, and earnings trending higher, the bull market looks positioned to extend into 2026,” said Gina Bolvin, President of Bolvin Wealth Management Group. “As more companies adopt AI, participation should broaden and sectors beyond the Magnificent Seven may start to show strength.”
Delivering a third consecutive interest-rate reduction on Wednesday, Fed Chair Jerome Powell voiced optimism that the US economy will strengthen as the inflationary impact from tariffs fades away. While officials maintained their outlook for just one cut in 2026, traders have stuck to bets for two such moves.
The Fed now expects the US economy to grow by 2.3% next year, up from its previous projection of 1.8%, while anticipating that the pace of inflation will slow to 2.4%.
An index of the dollar traded around a two-month low on Friday and was on track for a third weekly loss. Yields on 10-year Treasuries were little changed after a small gain on Thursday, when data showed that initial jobless claims rose more than expected in the Dec. 6 week.
“The Fed’s ‘hawkish-but-bullish’ cut last night reinforces this: stronger 2026 growth, faster disinflation,” said Florian Ielpo, head of macro at Lombard Odier Investment Managers. “Cuts are continuing, but they’re no longer automatic — and that’s usually a constructive backdrop for equities.”
In Asia, Thailand markets were in focus after Prime Minister Anutin Charnvirakul moved to dissolve parliament, setting the stage for an early election after reports of a key political party backing his minority government moving to withdraw its support.
Elsewhere, copper climbed to a fresh record high on Thursday and most other industrial metals rose after the Fed move. Gold steadied after three days of gains, supported by the prospect of further monetary easing in the US, while silver traded near a record high. Oil rallied from its lowest close in almost two months and Bitcoin flip-flopped in a tight range around $92,500.
The tech sector continues to be on traders’ radar after dominating much of the recent market action following Oracle Corp.’s results — which brought worries about valuations and whether heavy spending on AI infrastructure will pay off back into focus.
“The effect of Oracle has been greater than the Fed. This already tells us everything as we’ve been witnessing a strong concentration and one theme — AI — leading the market,” said Alberto Tocchio, a portfolio manager at Kairos Partners. “This doesn’t mean that AI is gone or it’s a bubble, but we need to focus on a wider scale.”
Corporate News
SoftBank Group Corp. is studying potential acquisitions including data center operator Switch Inc., as billionaire founder Masayoshi Son ramps up the search for deals that can help it ride the AI-fueled boom in digital infrastructure, people with knowledge of the matter said. Walt Disney Co. is licensing iconic characters including Mickey Mouse and Cinderella to OpenAI for use on its artificial intelligence video platform and has agreed to take a $1 billion stake in the startup. Huawei Technologies Co. and manufacturing partner Semiconductor Manufacturing International Corp. are making advances in chip production technology despite US attempts to limit their progress, according to analysis of a new phone’s components by research firm TechInsights. China’s internet search leader Baidu Inc. is seeing a fresh wave of bullish calls from analysts thanks to the possible listing of its chip unit Kunlunxin. OpenAI is rolling out a new artificial intelligence model designed to make ChatGPT better at coding, science and a wide range of work tasks, weeks after Alphabet Inc.’s Google put the startup on defense with the well-received launch of Gemini 3. Sembcorp Industries Ltd. agreed to buy Australian power generator and retailer Alinta Energy Pty for A$6.5 billion ($4.3 billion) in enterprise value, furthering the Singaporean company’s ambitions to expand outside its home market. Some of the main moves in markets:
Stocks
S&P 500 futures were little changed as of 11:30 a.m. Tokyo time Japan’s Topix rose 1.6% Australia’s S&P/ASX 200 rose 1.2% Hong Kong’s Hang Seng rose 1% The Shanghai Composite fell 0.4% Euro Stoxx 50 futures rose 0.3% Currencies
The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1734 The Japanese yen was little changed at 155.70 per dollar The offshore yuan was little changed at 7.0536 per dollar Cryptocurrencies
Bitcoin fell 0.5% to $92,380.85 Ether was little changed at $3,248.42 Bonds
The yield on 10-year Treasuries was little changed at 4.15% Australia’s 10-year yield was little changed at 4.72% Commodities
West Texas Intermediate crude rose 0.7% to $58.02 a barrel Spot gold fell 0.1% to $4,275.28 an ounce This story was produced with the assistance of Bloomberg Automation.
–With assistance from Joanna Ossinger and Richard Henderson.
©2025 Bloomberg L.P.
Continue Reading
-
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
HONG KONG, Dec. 11, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma.
This is the second international registrational study for cadonilimab, following the ongoing trial in immunotherapy-resistant hepatocellular carcinoma. COMPASSION-37 represents a pivotal advancement in cadonilimab’s global development and a concrete step in Akeso’s worldwide strategy, reinforcing its leadership in next-generation immuno-oncology. The company remains committed to its dual-track approach of proprietary development and strategic collaboration, leveraging global resources to accelerate cadonilimab’s international availability and expand accessible treatment options for patients worldwide.
Chemotherapy with or without PD-1 inhibitors, such as nivolumab, represents the international standard of care for advanced gastric cancer. However, the disease exhibits significant heterogeneity. While PD-1 treatment in combination with chemotherapy remains an effective treatment in many gastric cancer patients with high PD-L1 expression (CPS >5), its efficacy is markedly limited in gastric cancer patients with low PD-L1 expression (CPS <5) or negative PD-L1 expression (CPS <1). These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population.
In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the first-line treatment of advanced gastric cancer, restricting their use to PD-L1-positive patients. Authoritative guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), also prioritize recommending nivolumab-based regimens for patients with PD-L1 CPS ≥5. This underscores that treating advanced gastric cancer in PD-L1 low-expressing and negative patients has become a globally recognized clinical challenge.
In 2024, based on the COMPASSION-15 study results, cadonilimab in combination with chemotherapy was approved in China for the first-line treatment of gastric cancer, demonstrating benefit across all patient populations, including both PD-L1 positive and negative subgroups.
COMPASSION-15 is the only global Phase III clinical study in first-line advanced gastric cancer to have demonstrated survival benefit across all patient populations, irrespective of PD-L1 expression status. In this trial, patients with low PD-L1 expression and those who were PD-L1-negative accounted for as high as 49.8% and 23% of the enrolled population, respectively, significantly exceeding proportions observed in historical studies of its kind. The robust representation of low and negative PD-L1 patients in the study and the effective treatment of these patients validates cadonilimab’s broad-spectrum antitumor efficacy beyond PD-L1 dependency in gastric cancer.
Long-term follow-up data showed that cadonilimab plus chemotherapy significantly reduced the risk of death by 39% in the overall population compared to the control group (OS HR 0.61), regardless of PD-L1 status. In the PD-L1 CPS ≥5 subgroup, the reduction in mortality risk reached 51% (OS HR 0.49). Importantly, even among patients with low PD-L1 expression (CPS <5), a statistically significant 24% reduction in mortality risk was maintained (OS HR 0.76). These results were presented as an oral report at ESMO 2025. Earlier interim analysis data from the COMPASSION-15 study had been released as a prominent oral presentation at AACR 2024, with the full manuscript subsequently published in the Nature Medicine. These results highlight cadonilimab’s potential to elevate the current standard of tumor immunotherapy and address clinical challenges unmet by single-target agents.
Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
SOURCE Akeso, Inc.

Continue Reading
